Cutaneous malignant melanoma (CMM) is the most lethal form of skin cancer and accounts for approximately 78% of all skin cancer deaths. In the United States, the incidence of CMM has been increasing rapidly, and currently, CMM is the sixth and seventh most commonly diagnosed cancer among men and women, respectively.
1 According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, the estimated incidence of CMM in the United States in 1973 was 6.8 per 100 000 person-years, and this rate increased to 20.8 per 100 000 in 2005.
2 This increase in incidence is among the highest in SEER, with the exception of lung cancer in women. There are 4 major histologic subtypes of CMM. Superficial spreading melanoma (SSM) is the most common subtype, accounting for approximately 70% of cases, and occurs most often on the trunk. Nodular melanoma (NM) accounts for about 15% of melanomas and has only a vertical growth phase. Lentigo maligna melanoma (LMM) accounts for 13% of melanomas and correlates with long-term sun exposure in fair-skinned older individuals. Acral lentiginous melanoma (ALM) occurs predominantly on the nail beds, palms, and soles.
2,3